MH Group ＜9439＞: 196 yen (-7 yen)
The sharp decline continued. Financial results for the fiscal year ended 24/6 were announced after the end of trading the previous weekend. Operating profit was 0.023 billion yen, down 57.5% from the previous fiscal year. It seems that they are disgusted that it fell about 64% below the 0.065 billion yen increase of 19.3% as previously predicted, and landed due to a complete reversal or decline in profit. The fact that PB product sales in the BS salon management business fell below expectations, and increases in sales costs and labor costs resonated. Operating profit for the fiscal year ending 25/6 is expected to be 0.03 billion yen, up 29.6% from the previous fiscal year.
Sukegawa Electric ＜7711＞: 1,560 yen (+63 yen)
In the Nihon Keizai Shimbun, it is reported that the government will embark on revising the national strategy in order to advance the implementation period of nuclear fusion power generation, which is the next generation energy, and it seems to be clue material. The Cabinet Office's Nuclear Fusion Strategy Experts Meeting will resume on the 20th, and it is said that a new strategy will also be compiled during this fiscal year. The company is working on test equipment for nuclear fusion reactors, etc., and it seems that funds are going towards related brands.
Sumitomo Pharma ＜4506＞: 588 yen (+34 yen)
Significant continued growth. Daiwa Securities has raised the target stock price from 430 yen to 560 yen while continuing to be “neutral” in the middle with a 5-point evaluation. Core operating profit forecasts are 1.2 billion yen (company forecast 1 billion yen) for the fiscal year ending 25/3, 1.6 billion yen for the fiscal year ending 26/3, and 17.7 billion yen for the 29/3 fiscal year. Based on the results for the 1st quarter of the fiscal year ending 25/3, it seems that predictions for the diabetes treatment agent Twimig etc. were revised downward, while predictions for the prostate cancer treatment agent Orgovix and the overactive bladder treatment agent Gemtesa etc. were revised upward.
Pampasi HD ＜7532＞: 3,519 yen (-203 yen)
A sharp decline. Financial results for the fiscal year ended 24/6 were announced after the end of trading the previous weekend. Operating profit was 140.1 billion yen, up 33.2% from the previous fiscal year. It exceeded the previous forecast of 135 billion yen. An increase in duty-free sales and a recovery in event demand were the tailwinds. As for operating income for the fiscal year ending 25/6, operating profit is expected to increase 7.0% from the previous fiscal year to 150 billion yen. It falls below the market consensus of about 153 billion yen, and it seems that the profit increase rate remains in single digits compared to the drastic increase in profit in the previous fiscal year.
INPEX ＜1605＞: 2204 yen (-37.5 yen)
A sharp decline. WTI crude oil futures (September products) fell in the New York market the previous weekend, and it seems to be a factor holding back buyers. Concerns about the future of the US economy have receded, and while there is a view that demand for crude oil will remain steady, it is reported that practical discussions will resume in Cairo, the capital of Egypt, regarding the cease-fire negotiations in the Palestinian Autonomous Region of Gaza, and it seems that observations of a decline in crude oil prices due to easing tension in the Middle East are intensifying. It is reported on the 17th that the Israeli Prime Minister's Office showed a “cautious and optimistic” position towards the agreement.
Double A ＜7683＞: 2506 yen (+371 yen)
Significant continued growth. After the transaction ended on the 16th, it was announced that the stock split and shareholder benefit system would be expanded, and it was well received. It was announced that 1 share will be split into 2 shares using 8/31 as the reference date. The target of preferential treatment will be expanded to bags and shoe care products other than shoes, and brands eligible for shareholder benefits for shareholders holding 1 unit (100 shares) or more will be newly expanded to Himiko NICAL for shareholders holding 6 units (600 shares) or more after the stock split.
Fun Pep (4881): 156 yen (+8 yen)
rapid expansion. After the transaction ended on the 16th, it was announced that cosmetics containing the functional peptide “OSK9” of FunPep Healthcare, which is a consolidated subsidiary, will be sold by Albion, which is under the umbrella of KOSE, and they are viewed as good materials. It is blended into all 7 renewal products of Albion's skincare series “Infiness.” “Infiness” is a highly functional skin care series that combines science and technology, and has been developing products such as cleansers, toners, and serums that specialize in aging care since 2010.
AHC Group ＜7083＞: 1,416 yen (+110 yen)
Continued growth. It was announced that a stock buyback will be carried out after the transaction ends on the 16th, and it has been well received. The total number of shares to be acquired is limited to 30,000 shares (1.43% of the total number of issued shares excluding treasury stock) or 60,000 yen of the total acquisition price of shares, and the acquisition period is from 24/8/19 to 24/11/30. The improvement of capital efficiency and shareholder profits is positioned as one of the important management issues, and it is intended to carry out flexible capital policies in response to changes in the business environment.